Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Lapatinib MeSH Descriptor Data 2026


MeSH Heading
Lapatinib
Tree Number(s)
D03.633.100.786.516
Unique ID
D000077341
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077341
Scope Note
A quinazoline derivative that inhibits EPIDERMAL GROWTH FACTOR RECEPTOR and HER2 (ERB-B2 RECEPTOR TYROSINE KINASES) tyrosine kinases. It is used for the treatment of advanced or metastatic breast cancer, where tumors overexpress HER2.
Entry Term(s)
GW 282974X
GW 572016
GW-282974X
GW-572016
GW282974X
GW572016
Lapatinib Ditosylate
N-(3-chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
Tykerb
Pharm Action
Antineoplastic Agents
Tyrosine Kinase Inhibitors
Registry Numbers
0VUA21238F
0
G873GX646R
Public MeSH Note
2019; LAPATINIB was indexed under QUINAZOLINES 2004-2018
History Note
2019 (2004)
Date Introduced
2019/01/01
Last Updated
2026/01/01
Lapatinib Preferred
GW572016 Narrower
Lapatinib Ditosylate Narrower
Tykerb Narrower
GW 282974X Narrower
page delivered in 0.135s